Acarbose and canagliflozin on GLP1 secretion in PBH patients

• Research type

  Research Study

• Full title

  The effect of acarbose and canagliflozin on glucagon like peptide-1 secretion and hypoglycaemia in people with post bariatric hypoglycaemia

• IRAS ID

  334737

• Contact name

  Tricia Tan

• Contact email

  tricia.tan@nhs.net

• Sponsor organisation

  Imperial College Healthcare NHS Trust

• Duration of Study in the UK

  1 years, 6 months, 0 days

• Research summary

  Weight loss (bariatric) surgery is an effective treatment for obesity. Patients may develop low blood sugars repeatedly after the surgery which is called post bariatric surgery hypoglycaemia(PBH). It is thought to be related to the excessive secretion of glucagon-like peptide-1 (GLP-1) and insulin. There are currently no proper treatments for PBH.
  I am planning to test the effect of two medications, acarbose and canagliflozin, individually and together on their effect on the key hormone GLP-1. Acarbose slows the sugar digestion, reduces the GLP-1 production. Canagliflozin slows the absorption of glucose in the intestine and blunts the GLP1 secretion.
  I will recruit 12 PBH patients to have four separate study visits. All participants will be given all four treatments (one on each visit randomly). Arm A: no treatment; Arm B: Acarbose; Arm C:Canaglifozin; Arm D: Acarbose and Canagliflozin. One hour after the treatment, participants will take a standardised mixed meal test with Abbott Ensure Compact drink 125 ml. Blood samples will be taken prior to and after the Ensure Compact drink for glucose, insulin, GLP-1 levels. We will then analyse if these medications can reduce the GLP-1 level, hence the insulin secretion.

• REC name

  South West - Cornwall & Plymouth Research Ethics Committee

• REC reference

  24/SW/0038

• Date of REC Opinion

  23 Apr 2024

• REC opinion

  Further Information Favourable Opinion